Ann Pediatr Endocrinol Metab.  2013 Mar;18(1):13-18. 10.6065/apem.2013.18.1.13.

Response to three years of growth hormone therapy in girls with Turner syndrome

• Park HK
• Lee HS
• Ko JH
• Hwang IT
• Hwang JS

• KMID: 1429673
• DOI: http://doi.org/10.6065/apem.2013.18.1.13

Abstract

PURPOSE
Short stature is the most common finding in patients with Turner syndrome. Improving the final adult height in these patients is a challenge both for the patients and physicians. We investigated the clinical response of patients to growth hormone treatment for height improvement over the period of three years.
METHODS
Review of medical records from 27 patients with Turner syndrome treated with recombinant human growth hormone for more than 3 years was done. Differences in the changes of height standard deviation scores according to karyotype were measured and factors influencing the height changes were analyzed.
RESULTS
The response to recombinant human growth hormone was an increase in the height of the subjects to a mean value of 1.1 standard deviation for subjects with Turner syndrome at the end of the 3-year treatment. The height increment in the first year was highest. The height standard deviation score in the third year was negatively correlated with the age at the beginning of the recombinant human growth hormone treatment. Different karyotypes in subjects did not seem to affect the height changes.
CONCLUSION
Early growth hormone administration in subjects with Turner syndrome is helpful to improve height response to the treatment.

Keyword

Turner syndrome; Growth hormone; Treatment outcome

MeSH Terms

Adult
Growth Hormone
Human Growth Hormone
Humans
Karyotype
Medical Records
Treatment Outcome
Turner Syndrome
Growth Hormone
Human Growth Hormone

Figure

• 

  Fig. 1 Changes in height standard deviation scores for Korean Turner syndrome (TSSDS, continuous line) and normal population (standard deviation score [SDS], dashes) patients during growth hormone (GH) treatment. P-values indicate the differences between each point in time and the previous observation.

• 

  Fig. 2 Changes in standard deviation score for the height of Korean Turner syndrome patients according to the karyotypes of the subjects. GH, growth hormone.

• 

  Fig. 3 Relationship between the age at the commencementof growth hormone (GH) administration and the standard deviation scores of height at the third year.

Reference

1. Nielsen J, Wohlert M. Chromosome abnormalities found among 34,910 newborn children: results from a 13-year incidence study in Arhus, Denmark. Hum Genet. 1991; 87:81–83. PMID: 2037286.

2. Rochiccioli P, David M, Malpuech G, Colle M, Limal JM, Battin J, et al. Study of final height in Turner's syndrome: ethnic and genetic influences. Acta Paediatr. 1994; 83:305–308. PMID: 8038534.

3. Rongen-Westerlaken C, Corel L, van den Broeck J, Massa G, Karlberg J, Albertsson-Wikland K, et al. Swedish Study Group for GH treatment. Reference values for height, height velocity and weight in Turner's syndrome. Acta Paediatr. 1997; 86:937–942. PMID: 9343271.

4. Spiliotis BE. Recombinant human growth hormone in the treatment of Turner syndrome. Ther Clin Risk Manag. 2008; 4:1177–1183. PMID: 19337425.

5. Rosenfeld RG. Genentech National Cooperative Study Group. Growth hormone therapy in Turner's syndrome: an update on final height. Acta Paediatr Suppl. 1992; 383:3–6. PMID: 1458013.

6. Saenger P, Wikland KA, Conway GS, Davenport M, Gravholt CH, Hintz R, et al. Recommendations for the diagnosis and management of Turner syndrome. J Clin Endocrinol Metab. 2001; 86:3061–3069. PMID: 11443168.

7. Davenport ML. Approach to the patient with Turner syndrome. J Clin Endocrinol Metab. 2010; 95:1487–1495. PMID: 20375216.

8. Reiter EO, Blethen SL, Baptista J, Price L. Early initiation of growth hormone treatment allows age-appropriate estrogen use in Turner's syndrome. J Clin Endocrinol Metab. 2001; 86:1936–1941. PMID: 11344188.

9. Wasniewska M, De Luca F, Bergamaschi R, Guarneri MP, Mazzanti L, Matarazzo P, et al. Early treatment with GH alone in Turner syndrome: prepubertal catch-up growth and waning effect. Eur J Endocrinol. 2004; 151:567–572. PMID: 15538934.

10. Ranke MB, Lindberg A, Ferrandez Longas A, Darendeliler F, Albertsson-Wikland K, Dunger D, et al. Major determinants of height development in Turner syndrome (TS) patients treated with GH: analysis of 987 patients from KIGS. Pediatr Res. 2007; 61:105–110. PMID: 17211150.

11. Greulich WW, Pyle SI. Radiographic atlas of skeletal development of the hand and wrist. 2nd ed. Stanford: Stanford University Press;1959.

12. Shin JH, Kho CW, Kim DH, Kim JD, Kim HS, Park MJ, et al. Spontaneous growth in Korean patients with Turner syndrome. J Korean Soc Pediatr Endocrinol. 1998; 3:1–6.

13. Ranke MB, Lindberg A, Chatelain P, Wilton P, Cutfield W, Albertsson-Wikland K, et al. KIGS International Board Kabi International Growth Study. Prediction of long-term response to recombinant human growth hormone in Turner syndrome: development and validation of mathematical models. J Clin Endocrinol Metab. 2000; 85:4212–4218. PMID: 11095456.

14. Quigley CA, Crowe BJ, Anglin DG, Chipman JJ. Growth hormone and low dose estrogen in Turner syndrome: results of a United States multi-center trial to near-final height. J Clin Endocrinol Metab. 2002; 87:2033–2041. PMID: 11994337.

15. Hughes IP, Choong CS, Harris M, Ambler GR, Cutfield WS, Hofman PL, et al. Growth hormone treatment for Turner syndrome in Australia reveals that younger age and increased dose interact to improve response. Clin Endocrinol (Oxf). 2011; 74:473–480. PMID: 21375553.

16. Betts PR, Butler GE, Donaldson MD, Dunger DB, Johnston DI, Kelnar CJ, et al. UK KIGS Executive Group. A decade of growth hormone treatment in girls with Turner syndrome in the UK. Arch Dis Child. 1999; 80:221–225. PMID: 10325700.

17. Sas TC, de Muinck Keizer-Schrama SM, Stijnen T, Jansen M, Otten BJ, Hoorweg-Nijman JJ, et al. Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial. J Clin Endocrinol Metab. 1999; 84:4607–4612. PMID: 10599727.

18. Amundson E, Boman UW, Barrenas ML, Bryman I, Landin-Wilhelmsen K. Impact of growth hormone therapy on quality of life in adults with Turner syndrome. J Clin Endocrinol Metab. 2010; 95:1355–1359. PMID: 20080847.

19. Ross JL, Long LM, Loriaux DL, Cutler GB Jr. Growth hormone secretory dynamics in Turner syndrome. J Pediatr. 1985; 106:202–206. PMID: 4038513.

20. Lin TH, Kirkland JL, Kirkland RT. Growth hormone assessment and short-term treatment with growth hormone in Turner syndrome. J Pediatr. 1988; 112:919–922. PMID: 3373399.

21. Reiter JC, Craen M, Van Vliet G. Decreased growth hormone response to growth hormone-releasing hormone in Turner's syndrome: relation to body weight and adiposity. Acta Endocrinol (Copenh). 1991; 125:38–42. PMID: 1872123.

22. Ranke MB, Blum WF, Haug F, Rosendahl W, Attanasio A, Enders H, et al. Growth hormone, somatomedin levels and growth regulation in Turner's syndrome. Acta Endocrinol (Copenh). 1987; 116:305–313. PMID: 3687318.

23. Wit JM, Massarano AA, Kamp GA, Hindmarsh PC, van Es A, Brook CG, et al. Growth hormone secretion in patients with Turner's syndrome as determined by time series analysis. Acta Endocrinol (Copenh). 1992; 127:7–12. PMID: 1519426.

24. Rao E, Weiss B, Fukami M, Rump A, Niesler B, Mertz A, et al. Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nat Genet. 1997; 16:54–63. PMID: 9140395.

25. Blaschke RJ, Topfer C, Marchini A, Steinbeisser H, Janssen JW, Rappold GA. Transcriptional and translational regulation of the Leri-Weill and Turner syndrome homeobox gene SHOX. J Biol Chem. 2003; 278:47820–47826. PMID: 12960152.

26. Zinn AR, Tonk VS, Chen Z, Flejter WL, Gardner HA, Guerra R, et al. Evidence for a Turner syndrome locus or loci at Xp11.2-p22.1. Am J Hum Genet. 1998; 63:1757–1766. PMID: 9837829.

27. Ogata T, Muroya K, Matsuo N, Shinohara O, Yorifuji T, Nishi Y, et al. Turner syndrome and Xp deletions: clinical and molecular studies in 47 patients. J Clin Endocrinol Metab. 2001; 86:5498–5508. PMID: 11701728.

28. Chu CE, Paterson WF, Kelnar CJ, Smail PJ, Greene SA, Donaldson MD. Variable effect of growth hormone on growth and final adult height in Scottish patients with Turner's syndrome. Acta Paediatr. 1997; 86:160–164. PMID: 9055885.

29. Rosenfeld RG, Attie KM, Frane J, Brasel JA, Burstein S, Cara JF, et al. Growth hormone therapy of Turner's syndrome: beneficial effect on adult height. J Pediatr. 1998; 132:319–324. PMID: 9506648.

30. Chernausek SD, Attie KM, Cara JF, Rosenfeld RG, Frane J. Genentech, Inc, Collaborative Study Group. Growth hormone therapy of Turner syndrome: the impact of age of estrogen replacement on final height. J Clin Endocrinol Metab. 2000; 85:2439–2445. PMID: 10902791.

31. Chung SC, Park MJ, Kim DH. Final adult height in patients with Turner syndrome. J Korean Soc Pediatr Endocrinol. 1997; 2:60–69.

32. Shin JH, Kho CW, Kim DH, Kim JD, Kim HS, Kim HS, et al. Growth hormone therapy in girls with Turner syndrome; results of the Korean Turner Study Group. J Korean Soc Pediatr Endocrinol. 1998; 3:151–156.

33. Cowell CT, Dietsch S, Greenacre P. Growth hormone therapy for 3 years: the OZGROW experience. J Paediatr Child Health. 1996; 32:86–93. PMID: 8860379.

34. Bakker B, Frane J, Anhalt H, Lippe B, Rosenfeld RG. Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children. J Clin Endocrinol Metab. 2008; 93:352–357. PMID: 18000092.

35. Davenport ML, Crowe BJ, Travers SH, Rubin K, Ross JL, Fechner PY, et al. Growth hormone treatment of early growth failure in toddlers with Turner syndrome: a randomized, controlled, multicenter trial. J Clin Endocrinol Metab. 2007; 92:3406–3416. PMID: 17595258.

36. Linglart A, Cabrol S, Berlier P, Stuckens C, Wagner K, de Kerdanet M, et al. Growth hormone treatment before the age of 4 years prevents short stature in young girls with Turner syndrome. Eur J Endocrinol. 2011; 164:891–897. PMID: 21398400.

37. Lyon AJ, Preece MA, Grant DB. Growth curve for girls with Turner syndrome. Arch Dis Child. 1985; 60:932–935. PMID: 4062345.

38. Even L, Cohen A, Marbach N, Brand M, Kauli R, Sippell W, et al. Longitudinal analysis of growth over the first 3 years of life in Turner's syndrome. J Pediatr. 2000; 137:460–464. PMID: 11035821.

39. Davenport ML, Punyasavatsut N, Stewart PW, Gunther DF, Savendahl L, Sybert VP. Growth failure in early life: an important manifestation of Turner syndrome. Horm Res. 2002; 57:157–164. PMID: 12053087.

40. Bolar K, Hoffman AR, Maneatis T, Lippe B. Long-term safety of recombinant human growth hormone in Turner syndrome. J Clin Endocrinol Metab. 2008; 93:344–351. PMID: 18000090.